Morgan Stanley Maintains Equal-Weight on Immuneering, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on Immuneering (NASDAQ:IMRX) and kept the price target at $14.

August 04, 2023 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Immuneering and kept the price target at $14.
The news is directly about Immuneering and its rating by Morgan Stanley. The Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector. The maintained price target indicates that the analyst's view on the company has not changed. This could have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100